MedTrace Logo

Fixed-Dose Trial in Early Parkinson's Disease (PD)

NCT04201093 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 529

Last updated 2025-07-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics (PK) of 2 fixed doses of tavapadon and placebo in participants with early PD.

Conditions

  • Parkinson Disease

Interventions

DRUG

Tavapadon

Participants will be randomized to receive tavapadon 5mg tablet once daily orally for 27 weeks.

DRUG

Placebo

Participants will receive placebo matching to tavapadon QD orally for 27 weeks.

DRUG

Tavapadon

Participants will be randomized to receive tavapadon 15mg tablet once daily orally for 27 weeks.

Sponsors & Collaborators

Principal Investigators

  • ABBVIE INC., MD · AbbVie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-13
Primary Completion
2024-06-28
Completion
2024-06-28
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Bulgaria
  • Canada
  • Czechia
  • France
  • Germany
  • Israel
  • Italy
  • Poland
  • Spain
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04201093 on ClinicalTrials.gov